The updated draft guidance comes following recent research comparing induction times
News
Opdivo plus Yervoy moves closer to EU approval for dMMR/MSI-H colorectal cancer
CHMP recommended EU approval for combination treatment in its May decisions
Takeda’s dengue vaccine bags positive long-term efficacy results
Vaccine candidate demonstrated 83.6% efficacy against hospitalisation three years after vaccination
EC approves Ponvory for relapsing MS
European approval follows the recent announcement of the FDA approval of Ponvory for RMS
Biogen partners with Ginkgo Bioworks on gene therapy manufacturing platform
Collaboration will aim to address challenge of timely and costly AAV-based vector manufacturing
BMS’ Opdivo/Yervoy improves long-term survival for melanoma patients
At six and a half years 49% of patients treated with combination therapy remained alive
FDA approves Janssen’s Rybrevant
First targeted treatment authorised in the US for NSCLC patients with EGFR exon 20 insertion mutations
CHMP puts eight new medicines forward for EU approval
First one-time gene therapy for CALD among latest recommendations
MSD’s pneumococcal vaccine candidate shows promise in paediatric studies
Investigational 15-valent pneumococcal conjugate vaccine consists of pneumococcal polysaccharides from 15 serotypes
Lilly’s tirzepatide achieves superior A1C reductions versus insulin glargine
Investigational therapy also led to superior body weight reductions in adults with type 2 diabetes
EU secures 1.8 billion additional doses of Pfizer/BioNTech’s COVID-19 jab
Pfizer/BioNTech said all doses earmarked for the European Commission are planned to be manufactured in the European Union
NHS England funds first national metastatic breast cancer audit
UK-based charity Breast Cancer Now ‘proud’ of milestone after campaigning for improved data collection
CROY 2021 entering the final month for entries
The 2021 Clinical Researcher of the Year – The Americas will be closing for entry on the 18th of June.
EMA, MHRA to review Vertex’ Kaftrio for children with CF
If approved, up to 2,000 children with CF would be eligible for treatment with the drug
NICE turns down Janssen’s Erleada
Cost-effectiveness estimates have fallen above the threshold because of uncertain trial evidence
